Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization
Aims: Her‐2/neu testing is used as a marker for Herceptin® therapy. The aim was to investigate new dual‐colour chromogenic in situ hybridization (CISH), in a large number of breast carcinomas (n = 205) with DNA‐specific dual‐colour probes (ZytoVision, Bremerhaven, Germany) and to compare the result...
Gespeichert in:
| Veröffentlicht in: | Histopathology 2009-12, Vol.55 (6), p.716-723 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 723 |
|---|---|
| container_issue | 6 |
| container_start_page | 716 |
| container_title | Histopathology |
| container_volume | 55 |
| creator | Mayr, Doris Heim, Sibylle Weyrauch, Kerstin Zeindl-Eberhart, Evelyn Kunz, Anne Engel, Jutta Kirchner, Thomas |
| description | Aims: Her‐2/neu testing is used as a marker for Herceptin® therapy. The aim was to investigate new dual‐colour chromogenic in situ hybridization (CISH), in a large number of breast carcinomas (n = 205) with DNA‐specific dual‐colour probes (ZytoVision, Bremerhaven, Germany) and to compare the results with immunohistochemistry (n = 205) and fluorescence in situ hybridization (FISH) (n = 129).
Methods and results: Paraffin‐embedded tissue of 205 patients was used. After immunohistochemistry with a focus on immunohistochemically uncertain cases, Her‐2/neu amplification using dual‐colour CISH (ZytoVision®) was analysed. Validation by FISH was performed. The results were: immunohistochemistry, 27.8% with strong expression, 53.7% with uncertain overexpression and 18.5% with no expression; FISH, 25.6% amplified and 74.4% negative; CISH, 35.6% amplified, 62.9% negative and 1.5% not evaluable. Comparison of immunohistochemistry with CISH: CISH negative in 100% with immunohistochemistry 0/1+, amplified in 82.5% with immunohistochemistry 3+; 5.9% contradictory results: 4.4% immunohistochemistry 3+ and negative by CISH, 1.5% negative in immunohistochemistry but amplified by CISH; FISH (129 cases), 8.5% contradictory results to immunohistochemistry, 6.2% immunohistochemistry 3+ and negative by FISH, 2.3% negative by immunohistochemistry and amplified by FISH; comparison of CISH and FISH, 94.6% same results, 3.9% different ones, 1.6% CISH not analysable.
Conclusions: CISH, using dual‐colour probes (ZytoVision®) is as good as FISH for Her‐2/neu analysis. The few discrepant results are likely to be caused by polysomy or tumour heterogeneity. |
| doi_str_mv | 10.1111/j.1365-2559.2009.03427.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734194518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734194518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4367-ca3507d16f6cc8883a57b7f81a018d30a0d90140898e1f3df5520cf9a7fae58b3</originalsourceid><addsrcrecordid>eNqNkd9u0zAUhyMEYmXwCsg3iKtk_hPHMRIXqKLrxAChDU3ixnIcm7okdrETteUd905zaFVukMA3x5K_3znH-rIMIFigdC7WBSIVzTGlvMAQ8gKSErNi9yibnR4eZzNIIM8hqthZ9izGNYSIEYyfZmeIc4wpJ7Psfr4KvvfftbMKWAeiHUaw2jfBtvaXHKx3wPgAljrk-MLpMfdOTbSe4CZoGQegpFM6vAHK9xsZbEwZb4AETm9BO8ouV77zYwDqn6O2dlgB2_ej8ysbB69Wuk817IF0LTDd6IOOSqdxf2_wPHtiZBf1i2M9z74u3t_Ol_n158ur-bvrXJWkYrmShELWospUStV1TSRlDTM1khDVLYESthyiEta81siQ1lCKoTJcMiM1rRtynr0-9N0E_3PUcRBpTaW7TjrtxygYKREvKaoTWR9IFXyMQRuxCbaXYS8QFJNLsRaTMjEpE5NL8dul2KXoy-OQsel1-yd4lJeAV0dARiU7E5IHG08cxoinb_LEvT1wW9vp_X8vIJZXN9Mt5fNDPqnQu1Nehh-iYoRRcffpUny5-7ZY3Hy4FR_JA653z-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734194518</pqid></control><display><type>article</type><title>Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Mayr, Doris ; Heim, Sibylle ; Weyrauch, Kerstin ; Zeindl-Eberhart, Evelyn ; Kunz, Anne ; Engel, Jutta ; Kirchner, Thomas</creator><creatorcontrib>Mayr, Doris ; Heim, Sibylle ; Weyrauch, Kerstin ; Zeindl-Eberhart, Evelyn ; Kunz, Anne ; Engel, Jutta ; Kirchner, Thomas</creatorcontrib><description>Aims: Her‐2/neu testing is used as a marker for Herceptin® therapy. The aim was to investigate new dual‐colour chromogenic in situ hybridization (CISH), in a large number of breast carcinomas (n = 205) with DNA‐specific dual‐colour probes (ZytoVision, Bremerhaven, Germany) and to compare the results with immunohistochemistry (n = 205) and fluorescence in situ hybridization (FISH) (n = 129).
Methods and results: Paraffin‐embedded tissue of 205 patients was used. After immunohistochemistry with a focus on immunohistochemically uncertain cases, Her‐2/neu amplification using dual‐colour CISH (ZytoVision®) was analysed. Validation by FISH was performed. The results were: immunohistochemistry, 27.8% with strong expression, 53.7% with uncertain overexpression and 18.5% with no expression; FISH, 25.6% amplified and 74.4% negative; CISH, 35.6% amplified, 62.9% negative and 1.5% not evaluable. Comparison of immunohistochemistry with CISH: CISH negative in 100% with immunohistochemistry 0/1+, amplified in 82.5% with immunohistochemistry 3+; 5.9% contradictory results: 4.4% immunohistochemistry 3+ and negative by CISH, 1.5% negative in immunohistochemistry but amplified by CISH; FISH (129 cases), 8.5% contradictory results to immunohistochemistry, 6.2% immunohistochemistry 3+ and negative by FISH, 2.3% negative by immunohistochemistry and amplified by FISH; comparison of CISH and FISH, 94.6% same results, 3.9% different ones, 1.6% CISH not analysable.
Conclusions: CISH, using dual‐colour probes (ZytoVision®) is as good as FISH for Her‐2/neu analysis. The few discrepant results are likely to be caused by polysomy or tumour heterogeneity.</description><identifier>ISSN: 0309-0167</identifier><identifier>EISSN: 1365-2559</identifier><identifier>DOI: 10.1111/j.1365-2559.2009.03427.x</identifier><identifier>PMID: 19922593</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Biological and medical sciences ; breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Carcinoma - genetics ; Carcinoma - metabolism ; Chi-Square Distribution ; Chromogenic Compounds ; dual-colour CISH ; Female ; FISH ; Genital system. Mammary gland ; Gynecology. Andrology. Obstetrics ; Her-2/neu ; Humans ; immunohistochemistry ; Immunohistochemistry - methods ; In Situ Hybridization - methods ; Investigative techniques, diagnostic techniques (general aspects) ; Mammary gland diseases ; Medical sciences ; Neoplasm Staging ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Tumors</subject><ispartof>Histopathology, 2009-12, Vol.55 (6), p.716-723</ispartof><rights>2009 The Authors. Journal compilation © 2009 Blackwell Publishing Limited</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4367-ca3507d16f6cc8883a57b7f81a018d30a0d90140898e1f3df5520cf9a7fae58b3</citedby><cites>FETCH-LOGICAL-c4367-ca3507d16f6cc8883a57b7f81a018d30a0d90140898e1f3df5520cf9a7fae58b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2559.2009.03427.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2559.2009.03427.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22195079$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19922593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayr, Doris</creatorcontrib><creatorcontrib>Heim, Sibylle</creatorcontrib><creatorcontrib>Weyrauch, Kerstin</creatorcontrib><creatorcontrib>Zeindl-Eberhart, Evelyn</creatorcontrib><creatorcontrib>Kunz, Anne</creatorcontrib><creatorcontrib>Engel, Jutta</creatorcontrib><creatorcontrib>Kirchner, Thomas</creatorcontrib><title>Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization</title><title>Histopathology</title><addtitle>Histopathology</addtitle><description>Aims: Her‐2/neu testing is used as a marker for Herceptin® therapy. The aim was to investigate new dual‐colour chromogenic in situ hybridization (CISH), in a large number of breast carcinomas (n = 205) with DNA‐specific dual‐colour probes (ZytoVision, Bremerhaven, Germany) and to compare the results with immunohistochemistry (n = 205) and fluorescence in situ hybridization (FISH) (n = 129).
Methods and results: Paraffin‐embedded tissue of 205 patients was used. After immunohistochemistry with a focus on immunohistochemically uncertain cases, Her‐2/neu amplification using dual‐colour CISH (ZytoVision®) was analysed. Validation by FISH was performed. The results were: immunohistochemistry, 27.8% with strong expression, 53.7% with uncertain overexpression and 18.5% with no expression; FISH, 25.6% amplified and 74.4% negative; CISH, 35.6% amplified, 62.9% negative and 1.5% not evaluable. Comparison of immunohistochemistry with CISH: CISH negative in 100% with immunohistochemistry 0/1+, amplified in 82.5% with immunohistochemistry 3+; 5.9% contradictory results: 4.4% immunohistochemistry 3+ and negative by CISH, 1.5% negative in immunohistochemistry but amplified by CISH; FISH (129 cases), 8.5% contradictory results to immunohistochemistry, 6.2% immunohistochemistry 3+ and negative by FISH, 2.3% negative by immunohistochemistry and amplified by FISH; comparison of CISH and FISH, 94.6% same results, 3.9% different ones, 1.6% CISH not analysable.
Conclusions: CISH, using dual‐colour probes (ZytoVision®) is as good as FISH for Her‐2/neu analysis. The few discrepant results are likely to be caused by polysomy or tumour heterogeneity.</description><subject>Biological and medical sciences</subject><subject>breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - metabolism</subject><subject>Chi-Square Distribution</subject><subject>Chromogenic Compounds</subject><subject>dual-colour CISH</subject><subject>Female</subject><subject>FISH</subject><subject>Genital system. Mammary gland</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Her-2/neu</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>Immunohistochemistry - methods</subject><subject>In Situ Hybridization - methods</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Staging</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Tumors</subject><issn>0309-0167</issn><issn>1365-2559</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd9u0zAUhyMEYmXwCsg3iKtk_hPHMRIXqKLrxAChDU3ixnIcm7okdrETteUd905zaFVukMA3x5K_3znH-rIMIFigdC7WBSIVzTGlvMAQ8gKSErNi9yibnR4eZzNIIM8hqthZ9izGNYSIEYyfZmeIc4wpJ7Psfr4KvvfftbMKWAeiHUaw2jfBtvaXHKx3wPgAljrk-MLpMfdOTbSe4CZoGQegpFM6vAHK9xsZbEwZb4AETm9BO8ouV77zYwDqn6O2dlgB2_ej8ysbB69Wuk817IF0LTDd6IOOSqdxf2_wPHtiZBf1i2M9z74u3t_Ol_n158ur-bvrXJWkYrmShELWospUStV1TSRlDTM1khDVLYESthyiEta81siQ1lCKoTJcMiM1rRtynr0-9N0E_3PUcRBpTaW7TjrtxygYKREvKaoTWR9IFXyMQRuxCbaXYS8QFJNLsRaTMjEpE5NL8dul2KXoy-OQsel1-yd4lJeAV0dARiU7E5IHG08cxoinb_LEvT1wW9vp_X8vIJZXN9Mt5fNDPqnQu1Nehh-iYoRRcffpUny5-7ZY3Hy4FR_JA653z-g</recordid><startdate>200912</startdate><enddate>200912</enddate><creator>Mayr, Doris</creator><creator>Heim, Sibylle</creator><creator>Weyrauch, Kerstin</creator><creator>Zeindl-Eberhart, Evelyn</creator><creator>Kunz, Anne</creator><creator>Engel, Jutta</creator><creator>Kirchner, Thomas</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200912</creationdate><title>Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization</title><author>Mayr, Doris ; Heim, Sibylle ; Weyrauch, Kerstin ; Zeindl-Eberhart, Evelyn ; Kunz, Anne ; Engel, Jutta ; Kirchner, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4367-ca3507d16f6cc8883a57b7f81a018d30a0d90140898e1f3df5520cf9a7fae58b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biological and medical sciences</topic><topic>breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - metabolism</topic><topic>Chi-Square Distribution</topic><topic>Chromogenic Compounds</topic><topic>dual-colour CISH</topic><topic>Female</topic><topic>FISH</topic><topic>Genital system. Mammary gland</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Her-2/neu</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>Immunohistochemistry - methods</topic><topic>In Situ Hybridization - methods</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Staging</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayr, Doris</creatorcontrib><creatorcontrib>Heim, Sibylle</creatorcontrib><creatorcontrib>Weyrauch, Kerstin</creatorcontrib><creatorcontrib>Zeindl-Eberhart, Evelyn</creatorcontrib><creatorcontrib>Kunz, Anne</creatorcontrib><creatorcontrib>Engel, Jutta</creatorcontrib><creatorcontrib>Kirchner, Thomas</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Histopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayr, Doris</au><au>Heim, Sibylle</au><au>Weyrauch, Kerstin</au><au>Zeindl-Eberhart, Evelyn</au><au>Kunz, Anne</au><au>Engel, Jutta</au><au>Kirchner, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization</atitle><jtitle>Histopathology</jtitle><addtitle>Histopathology</addtitle><date>2009-12</date><risdate>2009</risdate><volume>55</volume><issue>6</issue><spage>716</spage><epage>723</epage><pages>716-723</pages><issn>0309-0167</issn><eissn>1365-2559</eissn><abstract>Aims: Her‐2/neu testing is used as a marker for Herceptin® therapy. The aim was to investigate new dual‐colour chromogenic in situ hybridization (CISH), in a large number of breast carcinomas (n = 205) with DNA‐specific dual‐colour probes (ZytoVision, Bremerhaven, Germany) and to compare the results with immunohistochemistry (n = 205) and fluorescence in situ hybridization (FISH) (n = 129).
Methods and results: Paraffin‐embedded tissue of 205 patients was used. After immunohistochemistry with a focus on immunohistochemically uncertain cases, Her‐2/neu amplification using dual‐colour CISH (ZytoVision®) was analysed. Validation by FISH was performed. The results were: immunohistochemistry, 27.8% with strong expression, 53.7% with uncertain overexpression and 18.5% with no expression; FISH, 25.6% amplified and 74.4% negative; CISH, 35.6% amplified, 62.9% negative and 1.5% not evaluable. Comparison of immunohistochemistry with CISH: CISH negative in 100% with immunohistochemistry 0/1+, amplified in 82.5% with immunohistochemistry 3+; 5.9% contradictory results: 4.4% immunohistochemistry 3+ and negative by CISH, 1.5% negative in immunohistochemistry but amplified by CISH; FISH (129 cases), 8.5% contradictory results to immunohistochemistry, 6.2% immunohistochemistry 3+ and negative by FISH, 2.3% negative by immunohistochemistry and amplified by FISH; comparison of CISH and FISH, 94.6% same results, 3.9% different ones, 1.6% CISH not analysable.
Conclusions: CISH, using dual‐colour probes (ZytoVision®) is as good as FISH for Her‐2/neu analysis. The few discrepant results are likely to be caused by polysomy or tumour heterogeneity.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19922593</pmid><doi>10.1111/j.1365-2559.2009.03427.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0309-0167 |
| ispartof | Histopathology, 2009-12, Vol.55 (6), p.716-723 |
| issn | 0309-0167 1365-2559 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734194518 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Biological and medical sciences breast cancer Breast Neoplasms - genetics Breast Neoplasms - metabolism Carcinoma - genetics Carcinoma - metabolism Chi-Square Distribution Chromogenic Compounds dual-colour CISH Female FISH Genital system. Mammary gland Gynecology. Andrology. Obstetrics Her-2/neu Humans immunohistochemistry Immunohistochemistry - methods In Situ Hybridization - methods Investigative techniques, diagnostic techniques (general aspects) Mammary gland diseases Medical sciences Neoplasm Staging Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism RNA, Messenger - genetics RNA, Messenger - metabolism Tumors |
| title | Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T09%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chromogenic%20in%20situ%20hybridization%20for%20Her-2/neu-oncogene%20in%20breast%20cancer:%20comparison%20of%20a%20new%20dual-colour%20chromogenic%20in%20situ%20hybridization%20with%20immunohistochemistry%20and%20fluorescence%20in%20situ%20hybridization&rft.jtitle=Histopathology&rft.au=Mayr,%20Doris&rft.date=2009-12&rft.volume=55&rft.issue=6&rft.spage=716&rft.epage=723&rft.pages=716-723&rft.issn=0309-0167&rft.eissn=1365-2559&rft_id=info:doi/10.1111/j.1365-2559.2009.03427.x&rft_dat=%3Cproquest_cross%3E734194518%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734194518&rft_id=info:pmid/19922593&rfr_iscdi=true |